Aesica Announces Strategic Partnership with Mitovie Pharma

10/10/2011

Leading pharmaceutical manufacturer, Aesica, has announced that it has formed a long-term strategic partnership with Mitovie Pharma throughout which, Aesica will deliver clinical trial and commercial batch supply and formulation development services.

Mitovie originally selected Aesica* to develop a number medicines in 2008 and following the successful delivery of the products, both companies have agreed to continue working together to develop further branded medicines and new medical devices, among other potential projects.

To date, Aesica’s Formulation Development team developed Glysmag ®, which is used to treat low blood magnesium (hypomagnesaemia) in several pharmaceutical forms, Optidine ™, an antiseptic wash used in operating theatres, Suptamid® developed for SOS treatment in epilepsy and the team is currently working on a new formulation of a patent protected innovation in the fields of anxiety, insomnia, sedation and severe, acute epileptic seizures.

The partnership is strategically important for both companies, as Aesica is able to provide Mitovie with a service provision that encompasses API and finished dosage manufacturing services, as well as formulation development expertise, and Mitovie can experience the added value and benefits of working with a single supplier.

Paul Titley, MD, Formulation Development, Aesica says: “We have worked with the team at Mitovie for almost three years and in that time have developed a number of novel concepts. To have been chosen by Mitovie as a long-term strategic partner is testament to the commitment of our team to provide fast, responsive bespoke solutions to development projects and to deliver the highest possible standards of service and quality. As our working relationship evolves we look forward to developing new concepts, applications and devices and we are seeking to further extend our sterile formulation development capability to enhance our service offering in this particular market to Mitovie.”

Michael Hawthorne, Chief Executive Officer, Mitovie Pharma adds: “We are very pleased with this development collaboration with Aesica as part of our commitment and drive to offer real medical solutions to clear medical challenges. We continue to be impressed by the skill and attitude of the team at Aesica. This partnership has already created innovative medicines that have helped patients, today. We see our partnership continue to grow as we identify new opportunities, such as sterile products and drug addiction, to work together for the benefit of our customers.”

Aesica is a leading full-service provider of development and manufacturing services for Formulated Products and Active Pharmaceutical Ingredients. The company develops long-term strategic partnerships with its clients, responds quickly and effectively to market demand and develops tailored solutions for specific requirements.

* Previously R5 Pharmaceuticals prior to its acquisition by Aesica in June 2010.